Barrot H Lambdin1, Jennifer Lorvick2, Jessie K Mbwambo3, John Rwegasha3, Saria Hassan4, Paula Lum5, Alex H Kral2. 1. RTI-International, San Francisco, CA , United States; University of California San Francisco, San Francisco, CA, United States; University of Washington, Seattle, WA, United States. Electronic address: blambdin@rti.org. 2. RTI-International, San Francisco, CA , United States. 3. Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 4. Yale University, New Haven, CT, United States. 5. University of California San Francisco, San Francisco, CA, United States.
Abstract
BACKGROUND: The government of Tanzania launched an opioid treatment program (OTP), using methadone, in Dar es Salaam in February of 2011. Hepatitis C virus (HCV) is a leading cause of morbidity and mortality globally, especially among people who inject drugs (PWID). We conducted a cross-sectional study among PWID engaged in OTP in Dar es Salaam to describe the prevalence and predictors of HCV antibody serostatus. METHODS: Routine programmatic data on patients enrolled in Muhimbili National Hospital's OTP clinic from February 2011 to January 2013 were utilized. Multivariable Poisson regression was used to examine factors associated with HCV antibody serostatus. RESULTS: A total of 630 PWID enrolled into the OTP clinic during the study period, seven percent of which were women. The overall seroprevalence of HCV antibody was 57% (95% Confidence interval: 53-61%). In adjusted analysis, methadone patients who used heroin for 5-10 years (adjusted prevalence ratio; aPR=1.41; 95% CI: 1.10-1.81) and >10years (aPR=1.48; 95% CI: 1.17-1.88) were more likely to be HCV antibody positive, compared to patients who used heroin for <5years. Patients who reported sharing needles or other equipment at their last injection (aPR=1.20; 95% CI: 1.01-1.41; p=0.022), being arrested (aPR=1.20; 95% CI: 1.04-1.40; p=0.012) and who were HIV-positive (aPR=1.84; 95% CI: 1.56-2.16; p<0.001) were also more likely to be HCV antibody positive than their counterparts. CONCLUSION: Our observed HCV antibody prevalence among PWID engaged in OTP is higher than previously reported estimates in Dar es Salaam. Predictors of HCV antibody serostatus in this sample were similar to those found among PWID in many other settings. Integrating HCV care and treatment into OTP clinics should be considered, leveraging lessons learned from the integration of HIV services into OTP. Global efforts to develop HCV care and treatment programs in low and middle-income countries are critical, especially among PWID who have a high burden of HCV.
BACKGROUND: The government of Tanzania launched an opioid treatment program (OTP), using methadone, in Dar es Salaam in February of 2011. Hepatitis C virus (HCV) is a leading cause of morbidity and mortality globally, especially among people who inject drugs (PWID). We conducted a cross-sectional study among PWID engaged in OTP in Dar es Salaam to describe the prevalence and predictors of HCV antibody serostatus. METHODS: Routine programmatic data on patients enrolled in Muhimbili National Hospital's OTP clinic from February 2011 to January 2013 were utilized. Multivariable Poisson regression was used to examine factors associated with HCV antibody serostatus. RESULTS: A total of 630 PWID enrolled into the OTP clinic during the study period, seven percent of which were women. The overall seroprevalence of HCV antibody was 57% (95% Confidence interval: 53-61%). In adjusted analysis, methadonepatients who used heroin for 5-10 years (adjusted prevalence ratio; aPR=1.41; 95% CI: 1.10-1.81) and >10years (aPR=1.48; 95% CI: 1.17-1.88) were more likely to be HCV antibody positive, compared to patients who used heroin for <5years. Patients who reported sharing needles or other equipment at their last injection (aPR=1.20; 95% CI: 1.01-1.41; p=0.022), being arrested (aPR=1.20; 95% CI: 1.04-1.40; p=0.012) and who were HIV-positive (aPR=1.84; 95% CI: 1.56-2.16; p<0.001) were also more likely to be HCV antibody positive than their counterparts. CONCLUSION: Our observed HCV antibody prevalence among PWID engaged in OTP is higher than previously reported estimates in Dar es Salaam. Predictors of HCV antibody serostatus in this sample were similar to those found among PWID in many other settings. Integrating HCV care and treatment into OTP clinics should be considered, leveraging lessons learned from the integration of HIV services into OTP. Global efforts to develop HCV care and treatment programs in low and middle-income countries are critical, especially among PWID who have a high burden of HCV.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Andrew A Adjei; Henry B Armah; Foster Gbagbo; William K Ampofo; Isaac K E Quaye; Ian F A Hesse; George Mensah Journal: J Med Microbiol Date: 2007-03 Impact factor: 2.472
Authors: Lisa G Johnston; Abigail Holman; Mohammed Dahoma; Leigh Ann Miller; Evelyn Kim; Mahmoud Mussa; Asha A Othman; Andrea Kim; Carl Kendall; Keith Sabin Journal: Int J Drug Policy Date: 2010-07-16
Authors: Farzana Kapadia; David Vlahov; Yingfeng Wu; Mardge H Cohen; Ruth M Greenblatt; Andrea A Howard; Judith A Cook; Lakshmi Goparaju; Elizabeth Golub; Jean Richardson; Tracey E Wilson Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten Journal: J Subst Abuse Treat Date: 2008-11-28
Authors: Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth Journal: Lancet Infect Dis Date: 2019-09-17 Impact factor: 25.071
Authors: Zameer Mohamed; John Rwegasha; Jin U Kim; Yusuke Shimakawa; Lila Poiteau; Stéphane Chevaliez; Sanjay Bhagani; Simon D Taylor-Robinson; Mark R Thursz; Jessie Mbwambo; Maud Lemoine Journal: J Viral Hepat Date: 2018-07-30 Impact factor: 3.728
Authors: Semvua B Kilonzo; Daniel W Gunda; David C Majinge; Hyasinta Jaka; Paulina M Manyiri; Fredrick Kalokola; Grahame Mtui; Elichilia R Shao; Fatma A Bakshi; Alex Stephano Journal: BMC Infect Dis Date: 2021-07-21 Impact factor: 3.090
Authors: Germana Henry Leyna; Neema Makyao; Alexander Mwijage; Angela Ramadhan; Samuel Likindikoki; Mucho Mizinduko; Melkizedeck Thomas Leshabari; Kåre Moen; Elia John Mmbaga Journal: Harm Reduct J Date: 2019-12-11